BIOCYTOGEN-B Shares Surge Over 12% Following Strategic Collaboration and Projected Four-Fold Profit Increase

Stock News03-24

BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 12.14% to HK$54.5, with a turnover of HK$160 million.

The surge follows an announcement on March 23 that BIOCYTOGEN-B has entered into a strategic collaboration agreement with Moonlight Bio, Inc., a Seattle-based biotechnology company focused on advanced cell therapies. The partnership aims to develop a new generation of cell therapies to address various challenging refractory cancers. Under the agreement, BIOCYTOGEN-B will provide fully human antibody molecules for therapeutic targets, while Moonlight Bio will be responsible for preclinical development of the related cell therapies.

Furthermore, BIOCYTOGEN-B previously issued its 2025 performance forecast, anticipating revenue of approximately RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to reach RMB 173 million, surging 416.37% compared to the previous year. The strong operational performance is attributed to continued expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126376045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 15:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126376045","market":"sg","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Surge Over 12% Following Strategic Collaboration and Projected Four-Fold Profit Increase","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 12.14% to HK$54.5, with a turnover of HK$160 million.</p>\n<p>The surge follows an announcement on March 23 that BIOCYTOGEN-B has entered into a strategic collaboration agreement with Moonlight Bio, Inc., a Seattle-based biotechnology company focused on advanced cell therapies. The partnership aims to develop a new generation of cell therapies to address various challenging refractory cancers. Under the agreement, BIOCYTOGEN-B will provide fully human antibody molecules for therapeutic targets, while Moonlight Bio will be responsible for preclinical development of the related cell therapies.</p>\n<p>Furthermore, BIOCYTOGEN-B previously issued its 2025 performance forecast, anticipating revenue of approximately RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to reach RMB 173 million, surging 416.37% compared to the previous year. The strong operational performance is attributed to continued expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Surge Over 12% Following Strategic Collaboration and Projected Four-Fold Profit Increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Surge Over 12% Following Strategic Collaboration and Projected Four-Fold Profit Increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 15:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 12.14% to HK$54.5, with a turnover of HK$160 million.</p>\n<p>The surge follows an announcement on March 23 that BIOCYTOGEN-B has entered into a strategic collaboration agreement with Moonlight Bio, Inc., a Seattle-based biotechnology company focused on advanced cell therapies. The partnership aims to develop a new generation of cell therapies to address various challenging refractory cancers. Under the agreement, BIOCYTOGEN-B will provide fully human antibody molecules for therapeutic targets, while Moonlight Bio will be responsible for preclinical development of the related cell therapies.</p>\n<p>Furthermore, BIOCYTOGEN-B previously issued its 2025 performance forecast, anticipating revenue of approximately RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to reach RMB 173 million, surging 416.37% compared to the previous year. The strong operational performance is attributed to continued expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1126376045","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126376045","pubTimestamp":1774335855,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 12.14% to HK$54.5, with a turnover of HK$160 million. The surge follows an announcement on March...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK0216":"研究试验","VXUS":"国际股票ETF-Vanguard","02315":"百奥赛图-B"},"translate_title":"战略合作并预计利润增长四倍后，百奥赛图-B股价飙升逾12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"VXUS":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 12.14% to HK$54.5, with a turnover of HK$160 million.\nThe surge follows an announcement on March 23 that BIOCYTOGEN-B has entered into a strategic collaboration agreement with Moonlight Bio, Inc., a Seattle-based biotechnology company focused on advanced cell therapies. The partnership aims to develop a new generation of cell therapies to address various challenging refractory cancers. Under the agreement, BIOCYTOGEN-B will provide fully human antibody molecules for therapeutic targets, while Moonlight Bio will be responsible for preclinical development of the related cell therapies.\nFurthermore, BIOCYTOGEN-B previously issued its 2025 performance forecast, anticipating revenue of approximately RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the company is expected to reach RMB 173 million, surging 416.37% compared to the previous year. The strong operational performance is attributed to continued expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth for the group.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126376045","isCrawlerRequest":true}